CalciMedica Inc. announced that its ongoing CARPO trial, a Phase 2b trial evaluating Auxora?? for the treatment of acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS), was expanded to clinical research sites in India and that the first patient has been enrolled there. Overseeing the trial in India as a member of the steering committee is Dr. Pramod Garg, Professor of Gastroenterology and Associate Dean of Research at the All India Institute of Medical Sciences in New Delhi, India.

CARPO is expected to enroll approximately 216 patients at more than 30 sites in the United States and India. The randomized, double-blind, placebo-controlled, dose-ranging trial is intended to demonstrate the tolerability and potential efficacy of Auxora in patients who have AP with accompanying SIRS, a condition that can be life-threatening and for which there is currently no approved therapy. Data from the CARPO trial are expected in the first half of 2024.